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Background/aim: Diabetes mellitus (DM) is a major health problem worldwide. Cinnamic acid (CA) and its derivatives are synthesized
in plants and increasing attention has been given to them in recent years due to the high number of beneficial health properties attributed
to their consumption. The aim of this study was to investigate the effects of CA on streptozotocin-induced diabetes in Wistar albino rats.
Materials and methods: DNA damage was evaluated in the blood, liver, and kidney cells of rats by the alkaline comet assay. Oxidative
stress parameters such as catalase, superoxide dismutase, glutathione reductase, glutathione-S-transferase, and glutathione peroxidase
activities and 8-hydroxy-2’-deoxyguanosine, total glutathione, and malondialdehyde levels; biochemical parameters including insulin,
total bilirubin, and BCA protein levels; hepatic enzyme levels such as alanine aminotransferase, aspartate aminotransferase, alkaline
phosphatase, and gamma-glutamyl transferase; and lipid profile parameters including high-density lipoprotein, low-density lipoprotein,
total cholesterol, and triglyceride levels were also evaluated.
Results: DM caused genotoxic damage and alterations in lipid profiles, oxidative stress parameters, and hepatic enzymes levels. CA
treatment ameliorated these effects.
Conclusion: It seems that CA might have a role in the prevention of the complications of diabetes.
Key words: Diabetes mellitus, DNA damage, oxidative stress, hepatic enzymes, lipid profile

1. Introduction
Diabetes mellitus (DM) is one of the major health problem
worldwide. It is characterized by hyperglycemia resulting
from deficiencies in insulin secretion and/or insulin
action (1). Chronic hyperglycemia can lead to a variety
of complications such as neuropathy, nephropathy, and
retinopathy and increased risk of cardiovascular diseases
(2). Globally, 2.8% of the world’s population suffers from
diabetes and this is predicted to be 5.4% by 2025 (3). In
Turkey, 7.4% of the population suffers from diabetes and it
is estimated that the number of patients will reach 9.6% of
the population by 2030 (4).
Studies on diabetes therapy have gained interest due
to its unwanted effects on quality of life, e.g., changing
lifestyles lead to reduced physical activity and increased
obesity (4). In diabetes treatment, the current drugs
have higher costs, limited efficacy and tolerability, and/
or significant side effects (5). As a result of these factors,
patients often have recourse to alternative forms of
* Correspondence: haticegulgoktas@gmail.com
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therapy such as herbal medicines. Herbal medicine usage
for diabetes treatment is especially common in West
Africa, Central America, and Asia (6,7). According to an
estimation published by the World Health Organization
(WHO), approximately 80% of diabetic patients presently
rely on herbal medicine for their treatment. Unfortunately,
pharmacological and toxicological evidence validating the
safety and efficacy of these medicinal plants is not readily
available (8).
Cinnamic acid (3-phenyl-2-propenoic acid, CA)
(Figure 1), a major component of Chinese cinnamon,
is a white crystalline phenolic compound with a lowintensity sweet, honey-like aroma (9). It exists in many
fruits, vegetables, and beverages including blueberry,
kiwi, cherry, plum, apple, pear, chicory, artichoke, potato,
cider, and coffee (10). CA and its derivatives possess a
variety of pharmacologic properties such as antioxidant,
hepatoprotective, antimalarial, and antityrosinase activities
(11,12). It was shown that they exert cytoprotective,
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Figure 1. Structure of CA.

antigenotoxic, and antioxidant effects in in vitro and
antitumor activities in experimental animal models
(13–15). They are important components of flavorings,
perfumes, synthetic dyes, and pharmaceuticals (16).
To our best knowledge, there was no study conducted
to investigate the effects of CA on DNA damage,
oxidative stress parameters, hepatic enzyme levels, and
lipid profiles in diabetic rats. Thus, the aim of this study
was to evaluate the protective role of CA on diabetesinduced oxidative damage in the blood, liver, and kidney
cells of rats. Diabetes was induced by streptozotocin
(STZ), a glucosamine–nitrosourea compound derived
from Streptomyces achromogenes that is used clinically as
a chemotherapeutic agent in the treatment of pancreatic
β-cell carcinoma. STZ damages pancreatic β cells, resulting
in hypoinsulinemia and hyperglycemia (17). In addition,
STZ is a source of free radicals that can also contribute to
DNA damage and subsequent cell death (18). In this study
the comet assay was used for the determination of DNA
damage. Oxidative stress parameters such as superoxide
dismutase (SOD), catalase (CAT), glutathione reductase
(GR), glutathione S-transferase (GST), and glutathione
peroxidase (GSH-Px) activities and 8-hydroxy-2’deoxyguanosine (8-OHdG), total glutathione (GSH), and
malondialdehyde (MDA) levels in the plasma, liver, and
kidney tissues; hepatic enzyme parameters such as alanine
aminotransferase (ALT), aspartate aminotransferase
(AST), alkaline phosphatase (AP), and gamma-glutamyl
transferase (GGT) levels in serum; and insulin levels in
plasma and blood lipid profiles such as triglyceride, total
cholesterol, high-density lipoprotein (HDL), and lowdensity lipoprotein (LDL) levels were also measured.
2. Materials and methods
2.1. Chemicals, kits, and equipment
The chemicals used in this study were purchased from
the following suppliers: normal melting agarose and
low melting point agarose from Boehringer Manheim
(Mannheim, Germany); sodium chloride (NaCl),
sodium hydroxide (NaOH), and potassium chloride
(KCl) from Merck Chemicals (Darmstadt, Germany);
dimethyl sulfoxide (DMSO), ethidium bromide (EtBr),
Triton-X-100, phosphate-buffered saline (PBS) tablets,
trichloroacetic acid, thiobarbituric acid, ALT assay kit,

AP kit, AST assay kit, GGT assay kit, insulin assay kit,
bicinchoninic acid (BCA) protein kit, HDL-LDL assay
kit, total cholesterol assay kit, triglyceride assay kit, STZ,
and CA from Sigma-Aldrich Chemicals (St Louis, MO,
USA); ethylenediaminetetraacetic acid disodium salt
dihydrate (EDTA-Na2), sodium lauroyl sarcosinate, and
Tris from ICN Biomedicals Inc. (Aurora, OH, USA);
8-OHdG assay kit, SOD assay kit, CAT assay kit, GR assay
kit, GSH-Px assay kit, GST assay kit, and GSH assay kit
from Cayman Chemicals Co. (Ann Arbor, MI, USA);
and ketamine hydrochloride from Eczacıbaşı (İstanbul,
Turkey). For spectrophotometric and spectrofluorometric
measurements SpectraMax M2 (Molecular Devices,
Sunnyvale, CA, USA) and for quantification SoftMax Pro
Software (Molecular Devices) were used.
2.2. Animals
Wistar albino rats (180–250 g, totally 24 rats) were used
in all experiments. They were housed in plastic cages with
stainless steel grid tops. Rats were maintained on a 12-h
light/dark cycle with controlled temperature (23 ± 2 °C)
and humidity (50%). Animals were fed with standard
laboratory chow and allowed to access feed and drinking
water ad libitum. The blood glucose levels of animals were
measured before the experiments. The animals were treated
humanely and with regard for alleviation of suffering and
the study was approved by the Ankara University Animal
Ethics Committee (2015-12-138).
2.3. Streptozotocin-induced diabetes mellitus model
Wistar rats were subjected to type 1 diabetes by STZ
injection (60 mg/kg freshly prepared in PBS) as previously
described (19). Two days later, blood was taken from tails
of rats using a lancet to measure the blood glucose levels
using a glucometer (Plusmed, İstanbul, Turkey). Rats
with a blood glucose level higher than 250 mg/dL were
considered to be diabetic.
2.4. Experimental design
The rats were divided into four groups:
Group 1: Sham group (n = 6). This group consisted of
animals treated with oral saline alone.
Group 2: Diabetic group (n = 6). This group consisted
of animals in which only diabetes was induced and the
animals were treated with oral saline.
Group 3: CA-treated group (n = 6). This group
consisted of animals treated with an oral dose of 50 mg/kg
b.w. CA in saline for 28 days.
Group 4: CA-treated diabetic group (n = 6). This group
consisted of animals treated with an oral dose of 50 mg/
kg b.w. CA in saline following the induction of diabetes
for 28 days.
The CA dose (50 mg/kg b.w. per os) was selected
according to our unpublished studies. At the end of
the experimental period, all animals were decapitated
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under anesthesia (90 mg/kg ketamine hydrochloride,
i.p.). Cardiac blood was collected into preservative-free
heparin tubes. Whole blood samples were obtained via
the intracardiac method. The serum was immediately
separated by centrifugation at 2000 rpm for 15 min. The
plasma was immediately separated by centrifugation
at 4000 rpm for 5 min at 4 °C. The serum and plasma
samples were stored at –80 °C until being assayed. Livers
and kidneys were removed. The organs were examined for
changes in size, color, and texture. The samples were kept
in the dark at 4 °C and processed within 4 h for comet
assay. The serum, plasma, liver, and kidney homogenates
were kept at –80 °C for the determination of oxidative
stress parameters, hepatic enzymes, and lipid profiles.
2.5. Comet assay (single-cell gel electrophoresis)
For the comet assay, blood samples and liver and kidney
homogenates were used. The liver and kidney tissues were
carefully dissected from their attachments and totally
excised. Preparation of a single-cell suspension from the
organs was performed according to standard procedures
(20,21). Briefly, approximately 0.2 g of each organ was
placed in 1 mL of chilled mincing solution (HBSS with 20
mM EDTA and 10% DMSO) in a petri dish and chopped
into pieces with a pair of scissors. The pieces were allowed
to settle and the supernatant containing the single-cell
suspension was taken. The concentrations of renal and
hepatic tissue cells in the supernatant were adjusted to
approximately 2 × 106 cells/mL in HBSS containing 20
mM EDTA/10% DMSO.
The basic alkaline comet assay of Tice et al. (21) as
further described by Bacanlı et al. (22) was performed. Cells
were embedded on agarose gel and lysed, and fragmented
DNA strands were drawn out by electrophoresis to form
a comet. After electrophoresis, the slides were neutralized
and then incubated in 50%, 75%, and 98% alcohol for 5
min each. The dried microscopic slides were stained with
EtBr (20 mg/mL in distilled water, 60 mL/slide) and scored
with a Leica fluorescence microscope (Wetzlar, Germany)
under green light. The microscope was connected to a
charge-coupled device camera and a personal computerbased analysis system (Comet Analysis Software, version
3.0, Kinetic Imaging Ltd., Liverpool, UK) to determine the
extent of DNA damage after electrophoretic migration of
the DNA fragments in the agarose gel. In order to visualize
DNA damage, 100 nuclei per slide were examined at 40×
magnification. Results were expressed as the percentage of
DNA in the tail (tail intensity).
2.6. Determination of biochemical parameters
The determination of insulin, total bilirubin, and BCA
protein levels in the plasma samples was performed
spectrophotometrically with assay kits at 450, 530, and 562
nm, respectively. Results were expressed as µIU/mL, mg/
dL, and µg/mL, respectively.
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2.7. Determination of liver enzyme levels
The determination of ALT, AST, AP, and GGT levels in
the serum samples was performed spectrophotometrically
with assay kits at 570, 450, and 418 nm, respectively.
Results were expressed as mU/mL.
2.8. Determination of lipid levels
The determination of HDL, LDL, total cholesterol, and
triglyceride levels in the serum samples was performed
spectrophotometrically with assay kits at 570 nm. Results
were expressed as µg/mL for HDL, LDL, and total
cholesterol and mg/dL for triglyceride levels.
2.9. Determination of oxidative stress parameters
Oxidative stress parameters were assayed in the plasma
samples and in liver and kidney homogenates. The liver
and kidney tissues were extracted, weighed, and subjected
to homogenization and sonication procedures (23). The
homogenates of the tissue samples were kept at –80 °C
until the time of analysis.
The determination of CAT, SOD, GR, GST, and
GSH-Px enzyme activities and GSH levels in the plasma
samples and liver tissues and 8-OHdG levels in the plasma
samples was performed spectrophotometrically using
kits following the manufacturer’s procedures at 540, 440,
340, 340, 420, 420, and 535 nm, respectively. Results were
expressed as mmol min–1 mg–1 for enzyme activities, µM
for GSH, pg/mL for 8-OHdG, and nmol/g for MDA levels.
2.10. Statistical analysis
Analysis of data was performed using SPSS 20.0
for Windows (IBM Corp., Armonk, NY, USA). The
distribution of the data was checked for normality using
the Kolmogorov–Smirnov test. The homogeneity of the
variance was verified by the Levene test. The differences
among the groups with normal distribution were evaluated
by the one-way analysis of variance (ANOVA) test and
post hoc analysis of group differences was performed by
the LSD test. The differences among the groups without
normal distribution were evaluated by Kruskal–Wallis
test. The results were given as mean ± standard deviation.
P < 0.05 was considered statistically significant.
3. Results
3.1. Comet assay
The DNA damage, expressed as tail intensity in the blood,
liver, and kidney cells of rats, is shown in Figure 2. In all
biological samples there were no statistically significant
differences in tail intensity between the sham group and
the CA-treated groups (P > 0.05). The DNA damage was
found significantly higher in the diabetic group compared
to the sham group (P < 0.05). CA treatment in the diabetic
group was found to decrease the DNA damage significantly
(P < 0.05).
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Figure 2. DNA damage of rats: A) blood cells; B) liver cells; C) kidney cells. The values are expressed as mean ± standard
deviation. a Statistically different from sham group (P < 0.05); b statistically different from diabetes group (P < 0.05).
Group 1: Sham; Group 2: diabetic rats; Group 3: CA (50 mg/kg)-treated rats; Group 4: CA (50 mg/kg)-treated diabetic rats.

3.2. Biochemical parameters
The insulin, total bilirubin, and BCA protein levels in
the plasma samples are shown in Table 1. The insulin
levels were significantly decreased in the diabetic group
compared to the sham group (P < 0.05) and the levels
increased significantly in the CA-treated diabetic group
compared to the diabetic group (P < 0.05).
There was no significant increase between the sham
and the diabetic group in the total plasma bilirubin and
plasma BCA protein levels.
3.3. Liver enzyme levels
The serum ALT, AST, AP, and GGT levels in the groups are
shown in Table 2.
The ALT, AST, AP, and GGT levels were significantly
increased in the diabetic group compared to the sham
group (P < 0.05). The serum AST levels in the CA-treated
diabetic group were found to be significantly lower than
in the diabetic group (P < 0.05). There were also decreases
in the levels of ALT, AP, and GGT in the CA-treated
diabetic group compared to the diabetic group, but these
differences were not statistically significant.
3.4. Lipid levels
The serum HDL, LDL, total cholesterol, and triglyceride
levels are shown in Table 3.
The LDL, total cholesterol, and triglyceride levels were
significantly higher in the diabetic group compared to the

sham group (P < 0.05). The LDL, total cholesterol, and
triglyceride levels in the serum samples of the CA-treated
diabetic group were found to be significantly lower than
in the diabetic group (P < 0.05). The HDL levels were
significantly decreased in the diabetic group compared to
the sham group (P < 0.05), but the HDL levels in the serum
samples of the CA-treated diabetic group were found to
significantly increase in the diabetic group (P < 0.05).
3.5. Oxidative stress parameters
The CAT, SOD, GR, GST, and GSH-Px enzyme activities;
the GSH and MDA levels in the plasma, liver, and kidney
tissues; and the plasma 8-OHdG levels are shown in Tables
4, 5, and 6, respectively.
The CAT, SOD, GSH-Px, and GST enzyme activities
and GSH levels were found to be significantly lower in the
diabetic group compared to the sham group (P < 0.05).
CAT, SOD, and GSH-Px enzyme activities and GSH levels
in the plasma, livers, and kidneys increased significantly
in the CA-treated diabetic group compared to the diabetic
group (P < 0.05). GST levels of the CA-treated diabetic
group were higher than in the diabetic group, but the
difference was not statistically significant. There was no
significant increase between the sham and CA-treated
diabetic groups.
Plasma 8-OHdG and MDA levels and plasma, hepatic,
and renal GR enzyme activities were found to significantly
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Table 1. Biochemical findings of plasma samples of experimental groups.
Insulin levels (µIU/mL)

Total bilirubin levels (mg/dL)

BCA protein levels (µg/mL)

Group 1

192.3 ± 50.9

4.3 ± 4.6

3668.3± 68.9

7.7 ± 10.8

3726.9 ± 25.0

2.2 ± 2.4

3731.9 ± 69.6

5.1 ± 3.9

3642.8 ± 35.1

Group 2

68.0 ± 65.7

Group 3

162.5 ± 51.0

Group 4

212.9 ± 40.7

a

b

The values are expressed as mean ± standard deviation; a statistically different from sham group (P < 0.05); b statistically
different from diabetes group (P < 0.05).
Group 1: Sham; Group 2: diabetic rats; Group 3: CA (50 mg/kg)-treated rats; Group 4: CA (50 mg/kg)-treated diabetic
rats.
BCA: Bicinchoninic acid.

Table 2. Liver enzyme levels of plasma samples of experimental groups.
ALT levels (mU/mL)

AST levels (mU/mL)

AP (mU/mL)

GGT levels (mU/mL)

Group 1

1984.4 ± 2348.2 b

79.1 ± 124.9 b

39.2 ± 14.0 b

1926.4 ± 1696.5 b

Group 2

8457.1 ± 8684.3

1535.8 ± 1924.7

Group 3

1369.7 ± 572.2 b

61.0 ± 76.1 b

Group 4

7480.9 ± 6711.0

659.4 ± 647.5

a

b

a

135.0 ± 24.0

a

4213.2 ± 4157.8 a

31.0 ± 6.1 b

759.4 ± 1324.1 b

89.4 ± 7.5

3191.0 ± 3196.3

The values are expressed as mean ± standard deviation; a statistically different from sham group (P < 0.05); b statistically
different from diabetes group (P < 0.05).
Group 1: Sham; Group 2: diabetic rats; Group 3: CA (50 mg/kg)-treated rats; Group 4: CA (50 mg/kg)-treated diabetic
rats.
ALT: Alanine aminotransferase; AST: aspartate aminotransferase; AP; alkaline phosphatase, GGT: gamma-glutamyl
transferase.

increase in the diabetes group compared to the sham group (P
< 0.05). The levels were found to significantly decrease in the
CA-treated diabetic group compared to the diabetic group (P
< 0.05). CA alone did not cause significant changes in any of
the studied oxidative stress parameters compared to the sham
group (P > 0.05).
4. Discussion
The antihyperglycemic activity of medicinal plants or plantderived products needs extensive research as the number of
diabetic patients is continuously on the rise according to WHO
projections (24). In animal studies, phenolic acids have been
reported to exert antiinflammatory, antioxidant, antidiabetic,
antimutagenic, anticarcinogenic, and body mass-reducing
activities. Cinnamic acid is the parent compound of its esters,
which are more volatile to be transported to other parts easily
(25,26).
It is known that oxidative stress results from an imbalance
between the generation of oxygen-derived radicals and
the antioxidant system. Numerous studies have shown
that diabetes is associated with increased formation of free
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radicals and decrease in antioxidant potential. In both types
of diabetes, oxidative stress is increased. Multiple factors can
cause oxidative stress in diabetes. The most important factor
is glucose autoxidation, leading to the production of free
radicals. Other factors include cellular oxidation/reduction
imbalances and reduction in antioxidant defenses (including
decreased cellular antioxidant levels and a reduction in the
activity of enzymes that dispose of free radicals). Another
important factor is the interaction of advanced glycation
end products (AGEs) with specific cellular receptors called
AGE receptors. Elevated levels of AGEs are formed under
hyperglycemic conditions. Their formation is initiated when
glucose interacts with specific amino acids on proteins,
forming a compound that then undergoes further chemical
reactions. Glycation of protein alters protein and cellular
function and the binding of AGEs to their receptors, which can
lead to modification in cell signaling and further production
of free radicals (27). The other nonenzymatic factors are
activation of NAD(P)H oxidases, nitric oxide synthase, and
a specific enzyme activity, xanthine oxidase, which produces
oxidant species and subsequent oxidative stress (28–30).
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Table 3. Lipid levels of serum samples of experimental groups.
HDL levels (µg/mL)

LDL levels (µg/mL)

Cholesterol levels (µg/mL)

Triglyceride levels (mg/dL)

Group 1

0.7 ± 0.1

0.3 ± 0.0

0.2 ± 0.0

159.0 ± 26.0 b

Group 2

0.3 ± 0.2 a

0.5 ± 0.0 a

0.7 ± 0.0 a

514.4 ± 289.0 a

Group 3

0.6 ± 0.2 b

0.3 ± 0.1 b

0.2 ± 0.0 b

167.7 ± 24.7 b

Group 4

0.5 ± 0.1

0.4 ± 0.0

0.2 ± 0.0

433.4 ± 54.0 a, b

b

b

b

b

b

b

The values are expressed as mean ± standard deviation; a statistically different from sham group (P < 0.05); b statistically different from
diabetes group (P < 0.05).
Group 1: Sham; Group 2: diabetic rats; Group 3: CA (50 mg/kg)-treated rats; Group 4: CA (50 mg/kg)-treated diabetic rats.
HDL: High-density lipoprotein; LDL: low-density lipoprotein.
Table 4. Oxidative stress parameters in the plasma samples of experimental groups.
Group 1

Group 2

Group 3

Group 4

CAT activity (nmol min–1 mL–1)

153.6 ± 13.2 b

89.2 ± 34.1 a

151.6 ± 4.7 b

151.9 ± 26.5 b

SOD activity (U/mL)

0.9± 0.6

0.4 ± 0.3

1.4 ± 0.2

0.8 ± 0.2 b

b

a

b

GSH-Px activity (nmol min–1 mL–1)

114.4± 2.4 b

42.4 ± 9.4 a

115.4 ± 1.1 b

95.1 ± 7.4 b

GR activity (nmol min mL )

2.4 ± 0.4

9.1 ± 3.4

2.9 ± 0.8

b

4.1 ± 1.8 b

GSH levels (µM)

4.1 ± 1.2 b

2.1 ± 0.1 a

4.2 ± 0.3 b

3.0 ± 0.9 b

GST (nmol min mL )

7.6 ± 0.7

3.7 ± 2.0

8-OHdG levels (ng/mL)
MDA levels (nmol/g)

–1

–1

–1

–1

b

b

11.1 ± 5.9

b

11.4 ± 4.1

b

a

8.9 ± 0.9

a

20.1 ± 7.0

a

26.4 ± 4.4

a

6.0 ± 2.0

10.4 ± 7.2

b

7.8 ± 2.0 a, b

11.7 ± 3.5

b

14.1 ± 2.6 b

The values are expressed as mean ± standard deviation; a statistically different from sham group (P < 0.05); b statistically
different from diabetes group (P < 0.05).
Group 1: Sham; Group 2: diabetic rats; Group 3: CA (50 mg/kg)-treated rats; Group 4: CA (50 mg/kg)-treated diabetic
rats
CAT: Catalase; SOD: superoxide dismutase; GSH-Px: glutathione peroxidase; GR: glutathione reductase; GSH:
glutathione; GST; glutathione S-transferase, 8-OHdG: 8-hydroxy-2’-deoxyguanosine; MDA: malondialdehyde.
Table 5. Oxidative stress parameters in the livers of experimental groups.
Group 1
CAT activity (nmol min mL )
–1

Group 2

15.1 ± 2.1

–1

SOD activity (U/mL)

Group 3

10.4 ± 4.7

b

0.4 ± 0.3 b

a

16.0 ± 2.1

Group 4
15.0 ± 3.9 b

b

0.2 ± 0.1 a

0.7 ± 0.2 b

56.5± 5.4

119.5 ± 3.4

0.4 ± 0.4 b

GSH-Px activity (nmol min mL )

124.1 ± 2.5

GR activity (nmol min–1 mL–1)

3.7 ± 1.2 b

11.3 ± 6.2 a

4.7 ± 3.8 b

6.3 ± 2.0 b

GSH levels (µM)

9.9 ± 3.6 b

5.4 ± 0.5 a

8.1 ± 4.4 b

7.8 ± 1.2 b

GST (nmol min mL )

7.6 ± 0.7

3.7 ± 2.0

MDA levels (nmol/g)

13.4 ± 5.1 b

–1

–1

–1

–1

b

b

a

a

24.3 ± 4.7 a

b

92.4 ± 8.8

b

73.4 ± 7.8

75.1 ± 8.4

15.2 ± 1.7 b

16.8 ± 3.1 b

The values are expressed as mean ± standard deviation; a statistically different from sham group (P < 0.05); b statistically
different from diabetes group (P < 0.05).
Group 1: Sham; Group 2: diabetic rats; Group 3: CA (50 mg/kg)-treated rats; Group 4: CA (50 mg/kg)-treated diabetic
rats.
CAT: Catalase; SOD: superoxide dismutase; GSH-Px: glutathione peroxidase; GR: glutathione reductase; GSH:
glutathione; GST; glutathione S-transferase, MDA: malondialdehyde.
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Table 6. Oxidative stress parameters in the kidneys of experimental groups.
Group 1

Group 2

Group 3

166.4 ± 8.2

SOD activity (U/mL)

0.8 ± 0.5 b

0.3 ± 0.0 a

GSH-Px activity (nmol min–1 mL–1)

149.4 ± 9.4 b

GR activity (nmol min mL )

4.4 ± 1.4

b

GSH levels (µM)

8.3 ± 0.6 b

5.3 ± 0.1 a

8.0 ± 0.3 b

GST (nmol min mL )

7.6 ± 0.7

3.7 ± 2.0

42.1 ± 10.4

MDA levels (nmol/g)

12.4 ± 4.0 b

–1

–1

–1

–1

–1

b

b

65.2 ± 3.7

Group 4

CAT activity (nmol min mL )
–1

a

167.0 ± 4.3

b

127.0 ± 23.5 a, b

0.8 ± 0.2 b

0.6 ± 0.3 b

64.4 ± 1.4 a

132.4 ± 1.1 b

130.4 ± 2.4

12.0 ± 3.4

5.0 ± 2.1

6.8 ± 1.1

a

a

23.8 ± 6.1 a

b

14.4± 5.7 b

b

b

7.9 ± 0.8 b
48.2 ± 11.4
14.8 ± 8.4 b

The values are expressed as mean ± standard deviation; a statistically different from sham group (P < 0.05); b
statistically different from diabetes group (P < 0.05).
Group 1: Sham; Group 2: diabetic rats; Group 3: CA (50 mg/kg)-treated rats; Group 4: CA (50 mg/kg)-treated
diabetic rats.
CAT: Catalase; SOD: superoxide dismutase; GSH-Px: glutathione peroxidase; GR: glutathione reductase; GSH:
glutathione; GST; glutathione S-transferase, MDA: malondialdehyde.

Numerous reports have documented elevations in
peroxide levels in plasma, red blood cells, and tissues
of animals with chemically induced diabetes (31,32).
In diabetic patients, both increases and decreases in the
activities of key antioxidant enzymes including CAT, SOD,
GSH-Px, and GR have been reported (33,34). In a pediatric
study, antioxidant activity was found to be decreased in
relation to poor glycemic control (35). It is also shown that
oxidative stress exists in diabetic patients, as evidenced by
increased total antioxidant capacity in the saliva and blood
of patients (36).
In the present study, we evaluated the ameliorative
effects of CA against STZ-induced diabetes and its
complications in Wistar albino rats. We found that STZinduced diabetes caused an increase in hepatic enzyme
(ALT, AST, AP, and GGT) levels and a decrease in
insulin levels compared to the sham group. There was no
significant increase between the sham and diabetic groups
in the total bilirubin levels of plasma samples. As far as we
know, this is the first study about the correlation between
diabetes and BCA protein levels. We found no significant
differences between the sham and diabetic groups in BCA
protein levels in the plasma samples. Diabetic rats have
significantly lower HDL but significantly higher LDL,
total cholesterol, and triglyceride levels when compared
to the sham group. When evaluating the oxidative stress
parameters, GSH levels and activities of CAT, SOD, GSHPx, and GST were significantly lower while 8-OHdG and
MDA levels and activities of GR were significantly higher
in the diabetic group compared to the sham group. CA
itself did not induce abnormalities in the oxidative stress
parameters. It also ameliorated the oxidative damage
induced by diabetes.
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Inhibition of α-glucosidase may be effective in diabetes
therapy. Due to this effect, mammalian α-glucosidase
inhibitors from natural sources can be beneficial in the
prevention and treatment of DM. Adisakwattana et al.
(37) demonstrated the α-glucosidase inhibitory activity
of cinnamic acid derivates against intestinal sucrase
inhibitors. It was shown that cinnamon extracts (50, 100,
150, and 200 mg/kg), which include CA significantly,
decreased the blood glucose and lipid levels in mice
(38). Ping et al. (39) studied the hypoglycemic effect of
cinnamon oil, which contains water-soluble polyphenol
type A polymer, cinnamaldehyde, and cinnamic acid as
active compounds, in a type 2 diabetic animal model.
They found that fasting blood glucose concentration was
significantly decreased in the 100 mg/kg group compared to
other groups. In addition, they found significant decreases
in plasma C-peptide, serum triglyceride, total cholesterol,
and blood urea nitrogen levels while serum HDL levels
were significantly increased after 35 days. Huang et al. (40)
reported that caffeic and cinnamic acids improved glucose
uptake in TNF-α-treated insulin-resistant FL83B cells. The
same group treated the mouse FL83B cells with TNF-α to
induce insulin resistance to evaluate the effects of caffeic
and cinnamic acids on glucose metabolism. They found
that caffeic and cinnamic acids increased the expression
of glycogen synthase, whereas the expression of glycogen
synthase kinase and phosphorylation of glycogen synthase
in Ser641 in insulin-resistant mouse hepatocytes was
decreased. The compounds suppressed the expression of
hepatic nuclear factor-4 in TNF-α-treated mouse FL83B
hepatocytes. They concluded that caffeic and cinnamic
acids ameliorated glucose metabolism by promoting
glycogenesis and inhibiting gluconeogenesis in TNF-α-
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treated insulin-resistant mouse hepatocytes (41). Rao
and Rao (42) reported the antihyperglycemic effect
of Syzygium alternifolium seeds, which contain CA.
Treatment with 50 mg/kg b.w. daily of fraction C (which
includes CA) for 30 days resulted in a significant decrease
in the fasting blood glucose levels of diabetic rats. The
altered enzyme activities of carbohydrate metabolism in
the livers and kidneys of diabetic rats were significantly
reverted to near normal levels by the administration of
fraction C (43). Adisakwattana et al. (44) reported that
CA and its derivatives (p-methoxycinnamic acid and
ferulic acid) have insulin-secreting activity in pancreatic
β cells. Cinnamaldehyde isolated from Cinnamomum
cassia has been shown to have hypoglycemic and
hypolipidemic effects in STZ-induced diabetic rats (45).
Lakshmi et al. (46) reported that CA activates insulinmediated glucose transport. Yibchok-anun et al. (47)
showed that oral administration of p-methoxycinnamic
acid (40–100 mg/kg) significantly decreased plasma
glucose and also increased plasma insulin concentrations
in both healthy and STZ-induced diabetic rats.
There are limited studies about genotoxic damage
caused by DM. In these studies, it is claimed that
reactive oxygen species production could cause DNA
damage in diabetes. Kushawa et al. (48) determined
the DNA damage in lung, liver, aorta, heart, kidney,
pancreas, and blood samples of experimentally induced
diabetic rats by standard comet, endonuclease III, and
formamidopyrimidine modified comet assays. They
showed that DNA damage was significantly higher in
the diabetic group compared to the nondiabetic group.

In this study, the DNA damage in the blood, liver, and
kidney cells in the diabetes-induced rats were found to
be higher compared to the sham group. CA treatment
(50 mg/kg daily, per os) was found to significantly
decrease the DNA damage in the blood, liver, and
kidney cells of the diabetic rats. Our results are in
accordance with previous reports about diabetes, its
complications, and the effects of natural antioxidants
against diabetes.
In conclusion, diabetes is affecting a significant
proportion of the population worldwide. It affects many
organs, including the pancreas, kidneys, and liver. The
disease is associated with a reduced quality of life and
increased risk factors for mortality and morbidity. In
diabetes treatment, traditional herbal folk medicines
are getting popular. Due to their antioxidant properties,
herbal products give positive and promising results.
With the overall results of the present study, we have
demonstrated that STZ-induced diabetic rats have DNA
damage and alterations in hepatic enzymes, lipid profiles,
and biochemical and oxidative stress parameters. CA
treatment was found to be protective against diabetesinduced damage in the blood, liver, and kidneys of rats.
Further in vitro, in vivo, and epidemiological studies are
required to clear up the role of CA in prevention and
management of diabetes and its complications.
Acknowledgment
This work was supported by the the Scientific and
Technological Research Council of Turkey (Grant
Number: 114S919).

References
1.

Eldar-Finkelman H, Kaidanovich O. The role of glycogen
synthase kinase-3 in insulin resistance and type 2 diabetes.
Expert Opin Ther Targets 2002; 6: 555-561.

6.

Yusuff KB, Obe O, Joseph BY. Adherence to anti-diabetic drug
therapy and self management practices among type-2 diabetics
in Nigeria. Pharm World Sci 2008; 30: 876-883.

2.

Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ,
Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA et al.
National, regional, and global trends in fasting plasma glucose
and diabetes prevalence since 1980: systematic analysis of
health examination surveys and epidemiological studies with
370 country-years and 2·7 million participants. Lancet 2011;
378: 31-40.

7.

Andrade-Cetto A, Heinrich M. Mexican plants with
hypoglycaemic effect used in the treatment of diabetes. J
Ethnopharmacol 2005; 99: 325-348.

8.

Ezuruike UF, Prieto JM. The use of plants in the traditional
management of diabetes in Nigeria: pharmacological and
toxicological considerations. J Ethnopharmacol 2014; 155:
857-924.

9.

Eilerman RG. Cinnamic acid, cinnamaldehyde, and cinnamyl
alcohol. In: Seidel A, editor. Kirk-Othmer Encyclopedia of
Chemical Technology. 5th ed. New York, NY, USA: John Wiley
& Sons, Inc.; 2001. pp. 595-603.

10.

Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L.
Polyphenols: food sources and bioavailability. Am J Clin Nutr
2004; 79: 727-747.

3.

Fatima A, Agrawal P, Singh PP. Herbal option for diabetes: an
overview. Asian Pac J Trop Dis 2012; 2: S536-S44.

4.

Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the
prevalence of diabetes for 2010 and 2030. Diabetes Res Clin
Pract 2010; 87: 4-14.

5.

Rotenstein LS, Kozak BM, Shivers JP, Yarchoan M, Close J,
Close KL. The ideal diabetes therapy: what will it look like?
How close are we? Clin Diabetes 2012; 30: 44-53.

175

ANLAR et al. / Turk J Med Sci
11.

Lee EJ, Kim SR, Kim J, Kim YC. Hepatoprotective
phenylpropanoids from Scrophularia buergeriana roots against
CCl4-induced toxicity: action mechanism and structureactivity relationship. Planta Med 2002; 68: 407-411.

12.

Wiesner J, Mitsch A, Wissner P, Jomaa H, Schlitzer M.
Structure-activity relationships of novel anti-malarial agents.
Part 2: cinnamic acid derivatives. Bioorg Med Chem Lett 2001;
12: 423-424.

24.

Rathmann W, Giani G. Global prevalence of diabetes: estimates
for the year 2000 and projections for 2030. Diabetes Care 2004;
27: 2568-2569.

25.

Hsu CL, Yen GC. Phenolic compounds: evidence for inhibitory
effects against obesity and their underlying molecular signaling
mechanisms. Mol Nutr Food Res 2008; 52: 53-61.

26.

Stalikas CD. Extraction, separation, and detection methods for
phenolic acids and flavonoids. J Sep Sci 2007; 30: 3268-3295.

13.

Banskota AH, Nagaoka T, Sumioka LY, Tezuka Y, Awale S,
Midorikawa K, Matsushige K, Kadota S. Antiproliferative
activity of the Netherlands propolis and its active principles in
cancer cell lines. J Ethnopharmacol 2002; 80: 67-73.

27.

Penckofer S, Schwertz D, Florczak K. Oxidative stress
and cardiovascular disease in type 2 diabetes: the role of
antioxidants and pro-oxidants. J Cardiovasc Nurs 2002; 16:
68-85.

14.

Cartron E, Carbonneau MA, Fouret G, Descomps B, Léger CL.
Specific antioxidant activity of caffeoyl derivatives and other
natural phenolic compounds: LDL protection against oxidation
and decrease in the proinflammatory lysophosphatidylcholine
production. J Nat Prod 2001; 64: 480-486.

28.

Desco MC, Asensi M, Márquez R, Martínez-Valls J, Vento
M, Pallardó FV, Sastre J, Viña J. Xanthine oxidase is involved
in free radical production in type 1 diabetes protection by
allopurinol. Diabetes 2002; 51: 1118-1124.

15.

Taner G, Özkan Vardar D, Aydin S, Aytaç Z, Başaran A, Başaran
N. Use of in vitro assays to assess the potential cytotoxic,
genotoxic and antigenotoxic effects of vanillic and cinnamic
acid. Drug Chem Toxicol 2017; 40: 183-190.

29.

16.

Bickers D, Calow P, Greim H, Hanifin J, Rogers A, Saurat J,
Sipes IG, Smith RL, Tagami H. A toxicologic and dermatologic
assessment of cinnamyl alcohol, cinnamaldehyde and cinnamic
acid when used as fragrance ingredients: the RIFM expert
panel. Food Chem Toxicol 2005; 43: 799-836.

Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M,
Aoki T, Etoh T, Hashimoto T, Naruse M et al. High glucose
level and free fatty acid stimulate reactive oxygen species
production through protein kinase C-dependent activation of
NAD(P)H oxidase in cultured vascular cells. Diabetes 2000; 49:
1939-1945.

30.

Cosentino F, Hishikawa K, Katusic ZS, Lüscher TF. High
glucose increases nitric oxide synthase expression and
superoxide anion generation in human aortic endothelial cells.
Circulation 1997; 96: 25-28.

31.

Armstrong D, Al-Awadi F. Lipid peroxidation and retinopathy
in streptozotocin-induced diabetes. Free Radic Biol Med 1991;
11: 433-436.

17.

Lenzen S. The mechanisms of alloxan-and streptozotocininduced diabetes. Diabetologia 2008; 51: 216-226.

18.

King AJ. The use of animal models in diabetes research. Br J
Pharmacol 2012; 166: 877-894.

32.

19.

Cumaoğlu A, Ozansoy G, Irat AM, Arıcıoğlu A, Karasu Ç,
Arı N. Effect of long term, non cholesterol lowering dose of
fluvastatin treatment on oxidative stress in brain and peripheral
tissues of streptozotocin-diabetic rats. Eur J Pharmacol 2011;
654: 80-85.

Rungby J, Flyvbjerg A, Andersen HB, Nyborg K. Lipid
peroxidation in early experimental diabetes in rats: effects of
diabetes and insulin. Acta Endocrinol 1992; 126: 378-380.

33.

Patel R, Shervington A, Pariente JA, Martinez‐Burgos MA,
Salido GM, Adeghate E, Salido GM, Adeghate E, Singh
J. Mechanism of exocrine pancreatic insufficiency in
streptozotocin‐induced type 1 diabetes mellitus. Ann N
Y Acad Sci 2006; 1084: 71-88.

Godin DV, Wohaieb SA. Reactive oxygen radical processes
in diabetes. In: Singal PK, editor. Oxygen Radicals in
the Pathophysiology of Heart Disease. Developments in
Cardiovascular Medicine. 1st ed. Boston, MA, USA: Springer;
1988. pp. 303-322.

34.

Godin DV, Wohaieb SA, Garnett ME, Goumeniouk A.
Antioxidant enzyme alterations in experimental and clinical
diabetes. Mol. Cell. Biochem 1988; 84: 223-231.

20.

21.

Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A,
Kobayashi H, Miyamae Y, Rojas E, Ryu JC, Sasaki YF. Single
cell gel/comet assay: guidelines for in vitro and in vivo genetic
toxicology testing. Environ Mol Mutagen 2000; 35: 206-221.

35.

Asayama K, Uchida N, Nakane T, Hayashibe H, Dobashi K,
Amemiya S, Kato K, Nakazawa S. Antioxidants in the serum of
children with insulin-dependent diabetes mellitus. Free Radic
Biol Med 1993; 15: 597-602.

22.

Bacanlı M, Aydın S, Taner G, Göktaş H, Şahin T, Başaran A,
Başaran N. Does rosmarinic acid treatment have protective
role against sepsis-induced oxidative damage in Wistar albino
rats? Hum Exp Toxicol 2016; 35: 877-886.

36.

23.

Sier C, Kubben F, Ganesh S, Heerding M, Griffioen G,
Hanemaaijer R, van Krieken JH, Lamers CB, Verspaget HW.
Tissue levels of matrix metalloproteinases MMP-2 and MMP9 are related to the overall survival of patients with gastric
carcinoma. Br J Cancer 1996; 74: 413-417.

Astaneie F, Afshari M, Mojtahedi A, Mostafalou S, Zamani MJ,
Larijani B, Abdollahi M. Total antioxidant capacity and levels
of epidermal growth factor and nitric oxide in blood and saliva
of insulin-dependent diabetic patients. Arch Med Res 2005; 36:
376-381.

37.

Adisakwattana S, Chantarasinlapin P, Thammarat H, YibchokAnun S. A series of cinnamic acid derivatives and their
inhibitory activity on intestinal α-glucosidase. J Enzyme Inhib
Med Chem 2009; 24: 1194-1200.

176

ANLAR et al. / Turk J Med Sci
38.

Kim SH, Hyun SH, Choung SY. Anti-diabetic effect of cinnamon
extract on blood glucose in db/db mice. J Ethnopharmacol
2006; 104: 119-123.

44.

Adisakwattana S, Moonsan P, Yibchok-Anun S. Insulinreleasing properties of a series of cinnamic acid derivatives in
vitro and in vivo. J Agric Food Chem 2008; 56: 7838-7844.

39.

Ping H, Zhang G, Ren G. Antidiabetic effects of cinnamon oil
in diabetic KK-Ay mice. Food Chem Toxicol 2010; 48: 23442349.

45.

Babu PS, Prabuseenivasan S, Ignacimuthu S. Cinnamaldehyde—a
potential antidiabetic agent. Phytomedicine 2007; 14: 15-22.

40.

Huang DW, Shen SC, Wu JSB. Effects of caffeic acid and
cinnamic acid on glucose uptake in insulin-resistant mouse
hepatocytes. J Agric Food Chem 2009; 57: 7687-7692.

46.

41.

Huang DW, Shen SC. Caffeic acid and cinnamic acid
ameliorate glucose metabolism via modulating glycogenesis
and gluconeogenesis in insulin-resistant mouse hepatocytes. J
Funct Foods 2012; 4: 358-366.

Lakshmi BS, Sujatha S, Anand S, Sangeetha KN, Narayanan
RB, Katiyar C, Kanaujia A, Duggar R, Singh Y, Srinivas K.
Cinnamic acid, from the bark of Cinnamomum cassia, regulates
glucose transport via activation of GLUT4 on L6 myotubes in a
phosphatidylinositol 3‐kinase‐independent manner. J Diabetes
2009; 1: 99-106.

47.

Yibchok‐anun S, Adisakwattana S, Moonsan P, Hsu WH.
Insulin‐secretagogue activity of p‐methoxycinnamic acid in
rats, perfused rat pancreas and pancreatic β‐cell line. Basic Clin
Pharmacol Toxicol 2008; 102: 476-482.

48.

Kushwaha S, Vikram A, Trivedi P, Jena G. Alkaline, Endo III
and FPG modified comet assay as biomarkers for the detection
of oxidative DNA damage in rats with experimentally induced
diabetes. Mutat Res Genet Toxicol Environ Mutagen 2011; 726:
242-250.

42.

43.

Rao BK, Rao CA. Hypoglycemic and antihyperglycemic
activity of Syzygium alternifolium (Wt.) Walp. seed extracts in
normal and diabetic rats. Phytomedicine 2001; 8: 88-93.
Kasetti RB, Rajasekhar MD, Kondeti VK, Fatima SS, Kumar
EGT, Swapna S, Ramesh B, Rao CA. Antihyperglycemic and
antihyperlipidemic activities of methanol:water (4:1) fraction
isolated from aqueous extract of Syzygium alternifolium seeds
in streptozotocin induced diabetic rats. Food Chem Toxicol
2010; 48: 1078-1084.

177

